Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The June 2009 monograph topics are everolimus; Japanese encephalitis vaccine, inactivated; inhaled insulin; pitavastatin; and dabigatran etexilate. The DUE is on plerixafor.
Get full access to this article
View all access options for this article.
References
1.
Vimpat [package insert].Smyrna, GA: UCB, Inc; October 2008.
2.
UCB announces FDA filing for lacosamide in the treatment of partial onset seizures in adults with epilepsy [news release].Brussels, Belgium: UCB, Inc; November 29, 2007. http://www.ucb.com/news/2810.asp. Accessed January 15, 2008.
3.
UCB announces FDA filing for lacosamide in the treatment of diabetic neuropathic pain [news release].Brussels, Belgium: UCB, Inc; November 29, 2007. http://www.ucb.com/news/2809.asp. Accessed January 15, 2008.
4.
Ben-MenachemE., BitonV., JatuzisD., Abou-KhalilB., DotyP., RuddG.D.Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia.2007; 48(7): 1308–1317.
StoehrT., HeersC., StablesJ., WilcoxK., WhiteS.Preclinical profile of the novel anticonvulsant lacosamide [abstract]. Epilepsia.2006; 47(Suppl 3): 84–85.
11.
ErringtonA.C., CoyneL., StohrT., SelveN., LeesG.Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology.2006; 50(8): 1016–1029.
12.
StoehrT., ShandraP., KashenkoO., ShandraA.Synergism of lacosamide and first-generation and novel antiepileptic drugs in the 6 Hz seizure model in mice [abstract]. Epilepsia.2007; 48(Suppl 6): 252.
13.
StoehrT., StablesJ.P., WilcoxK., WhiteH.S.The pre-clinical profile of the novel anticonvulsant lacosamide [abstract]. Epilepsia.2005; 46(Suppl 6): 373–374.
14.
StoehrT., KupferbergH.J., StablesJ.P.Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res.2007; 74(2-3): 147–154.
15.
BrandtC., HeileA., PotschkaH., StoehrT., LoscherW.Effects of the novel antiepileptic drug lacosamide on the development of amygdale kindling in rats. Epilepsia.2006; 47(11): 1803–1809.
16.
DuncanG.E., KohnH.The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res.2005; 67(1-2): 81–87.
17.
BeyreutherB., CallizotN., StohrT.Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain. Arthritis Res Ther.2007; 9(1): R14.
18.
BeyreutherB.K., CallizotN., BrotM.D., FeldmanR., BainS.C., StohrT.Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur J Pharmacol.2007; 565(1-3): 98–104.
19.
BeyreutherB.K., GeisC., StohrT., SommerC.Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. Neuropharmacology.2007; 52(5): 1312–1317.
20.
BeyreutherB., CallizotN., StohrT.Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol.2006; 539(1-2): 64–70.
21.
HaoJ.X., StohrT., SelveN., Wiesenfeld-HallinZ., XuX.J.Lacosamide, a new antiepileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur J Pharmacol.2006; 553(1-3): 135–140.
22.
FreitagJ., StoehrT.Anti-tremor effects of the investigational antiepileptic drug lacosamide on harmaline-induced tremors in rats [abstract]. Eur J Neurology.2006; 13(Suppl 2): 87.
23.
StoehrT.Lacosamide has potent anti-tremor effects in a rat model for essential tremor [abstract]. Neurology.2006; 66(Suppl 2): A253.
24.
StoehrT.Lacosamide reduces tardive dyskinesia in a mouse model [abstract]. Movement Dis.2006; 21(Suppl 15): S373.
25.
StoehrT.Potent anti-tremor effects of lacosamide in a rat model for essential tremor [abstract]. Movement Dis.2006; 21(Suppl 15): S703.
26.
StohrT., LekieffreD., FreitagJ.Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats. Eur J Pharmacol.2008; 589(1-3): 114–116.
BitonV., RosenfeldW., MameniskieneR.Multicenter, double-blind, double-dummy trial investigating safety, tolerability and pharmacokinetics of intravenous SPM 927 in subjects with partial seizures [abstract]. Epilepsia.2006; 47(Suppl 3): 12–13.
29.
ThomasD., ScharfeneckerU., SchiltmeyerB., DotyP., CawelloW., HorstmannR.Low potential for drug-drug-interaction of lacosamide [abstract]. Epilepsia.2006; 47(Suppl 4): 200.
30.
BitonV., RosenfeldW.E., WhitesidesJ., FountainN.B., VaicieneN., RuddG.D.Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia.2008; 49(3) 418–424.
31.
Ben-MenachemE.Lacosamide—efficacy and safety results in adults with partial-onset seizures [abstract]. Epilepsia.2007; 48(Suppl 7): 176.
32.
ChungS.S., SperlingM., BitonV., KraussG., BeamanM., HebertD.Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures [abstract]. Epilepsia.2007; 48(Suppl 6): 321.
33.
HalaszP., KalvianenR., Mazurkiewicz-BeldzinskaM., RosenowF., DotyP., SullivanT.Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures [abstract]. Epilepsia.2006; 47(Suppl 4): 3.
34.
RosenfeldW., FountainN.B., KaubrysG., HeinzenL., McSheaC.Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures [abstract]. Epilepsia.2007; 48(Suppl 6): 318–319.
35.
RosenfeldW., FountainN., KaubrysG., HeinzenL., McSheaC.Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures [abstract]. Eur J Neurol.2008; 15(Suppl 3): 13.
36.
KraussG., Ben-MenachemE., MameniskieneR., VaicieneN., BrockM., WhitesidesJ.Intravenous lacosamide (SPM 927) as replacement for oral lacosamide in subjects with partial seizures: a multicenter, open-label, inpatient safety and tolerability trial [abstract]. Epilepsia.2006; 47(Suppl 4): 163.
37.
VaicieneN., MameniskieneR., BitonV., BrockM., SommervilleK.Multicenter open-label trial investigating safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures [abstract]. Epilepsia.2006; 47(Suppl 3): 146.
38.
KraussG., Ben-MenachemE., MameniskieneR., VaicieneN., WhitesidesJ., BrockM.Intravenous lacosamide as replacement for oral lacosamide in subjects with partial-onset seizures: a multicenter, open-label, inpatient safety and tolerability trial [abstract]. Neurology.2007; 68(Suppl 1): A125.
39.
FryeW., SimpsonJ., ShaibaniA., KochB.; SP665 Study Group. The safety and efficacy of lacosamide in the long-term treatment of diabetic neuropathic pain [abstract]. Neurology.2006; 66(Suppl 2): A203.
40.
ShaibaniA., BitonV., RauckR., KochB., SimpsonJ.Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial [published online ahead of print July 10, 2008]. Eur J Pain. DOI: 10.1016/j.ejpain.2008.05.016.
41.
WymerJ., GarrisonC., SimpsonJ., KochB.; SP742 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of lacosamide in subjects with painful distal diabetic neuropathy [abstract]. Neurology.2006; 66(Suppl 2): A202.
42.
WymerJ., GarrisonC., SimpsonJ., KochB.Efficacy and safety of lacosamide in painful distal diabetic neuropathy [abstract]. Diabetes.2007; 56(Suppl 1): A158.
43.
ShaibaniA., KenneyP., SimpsonJ., BongardtS.Lacosamide in painful distal diabetic neuropathy: results of a multicenter, placebo-controlled US trial [abstract]. Eur J Neurology.2007; 14(Suppl 1): 250.
44.
GrafR., FryeW., SimpsonJ.Lacosamide in long-term treatment of painful diabetic neuropathy (DNP) [abstract]. Eur J Neurol.2007; 14(Suppl 1): 260.
45.
BongardtS., BainS., TzschaschelB., SommervilleK.Lacosamide reduces pain in subjects with diabetic neuropathic pain [abstract]. Ann Neurol.2008; 64(Suppl 12): S25.
46.
HidvegiT., BretschneiderM., ThierfelderS., SommervilleK., BongardtS.Long-term efficacy of lacosamide in subjects with painful distal diabetic neuropathy [abstract]. Eur J Neurol.2008; 15(Suppl 3): 324.
47.
KrebsfaengerN., StoehrT.Lacosamide an investigational anticonvulsant, has a favorable profile in preclinical reproductive, developmental and juvenile toxicity studies [abstract]. Epilepsia.2007; 48(Suppl 6): 363–364.
48.
BitonV., FountainN., RosenowF.Safety and tolerability of lacosamide: summary of adverse events in epilepsy clinical trials [abstract]. Ann Neurol.2008; 64(Suppl 12): S21.
49.
JatuzisD., BitonV., Ben-MenachemE., Abou-KhalilB., DotyP., RuddG.D.Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures [abstract]. Epilepsia.2005; 46(Suppl 8): 170.
50.
KalviainenR., HalaszP., Mazurkiewicz-BeldzinskaM., RosenowF., HoepkenB., RuddG.D.Oral lacosamide: evaluation of effect on concomitant antiepileptic drug plasma concentrations in subjects with partial-onset seizures [abstract]. Eur J Neurol.2007; 14(Suppl 1): 86.
51.
ThomasD., SchiltmeyerB., CawelloW., HammesW., HorstmannR.Lacosamide has no potential for interaction with metformin [abstract]. Diabetes.2007; 56(Suppl 1): A572.
